SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patien
How this was made
The 30-second read
Why it matters
The filing supplies fresh earnings data and a timeline for pivotal trial results, which are key catalysts for the stock's near‑term direction.
Market read
Primary disclosure of earnings and upcoming trial milestones; relevant for biotech traders monitoring AML pipeline developments.
What to watch
Cash runway of $134.7 M provides ample funding for upcoming trials, reducing near‑term dilution risk.
SELLAS reports Q3 2026 net loss of $(10,091) thousand, up from $(6,791) thousand, with cash and cash equivalents of $134,711 thousand at September 30, 2026; Phase 3 REGAL topline results expected in November 2026
The filing reports no revenue. Operating expenses and the net loss rose sharply year over year for both the quarter and the nine months, and the company attributes the R&D increase to preparation for a potential BLA. Balance sheet strength is printed (cash of $134,711 thousand and total stockholders' equity of $131,805 thousand), but the outcome of the pending Phase 3 REGAL topline readout is not reported in this document.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, Q3 2026 (three months ended Sep 30, 2026)GAAP | $7.03M | – | – |
| General and administrative expenses, Q3 2026 (three months ended Sep 30, 2026)GAAP | $4.28M | – | – |
| Total operating expenses, Q3 2026 (three months ended Sep 30, 2026)GAAP | $11.31M | – | – |
| Loss from operations, Q3 2026 (three months ended Sep 30, 2026)GAAP | −$11.31M | – | – |
| Interest income, Q3 2026 (three months ended Sep 30, 2026)GAAP | $1.22M | – | – |
| Net loss, Q3 2026 (three months ended Sep 30, 2026)GAAP | −$10.09M | – | – |
| Net loss per common share, basic and diluted, Q3 2026 (three months ended Sep 30, 2026)GAAP | $(0.05) | – | – |
| Research and development expenses, nine months ended Sep 30, 2026GAAP | $18.43M | – | – |
| General and administrative expenses, nine months ended Sep 30, 2026GAAP | $12.76M | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $31.19M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$31.19M | – | – |
| Interest income, nine months ended Sep 30, 2026GAAP | $3.09M | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | −$28.10M | – | – |
| Net loss per common share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(0.15) | – | – |
Capital returns
- No share repurchases or dividends are reported in the document.
What drove it
- Company's explanation for the R&D increase: primarily due to increases in manufacturing costs, clinical and regulatory consulting, and clinical trial expenses in preparation for a potential Biologics License Application (BLA) for GPS following the final analysis of the REGAL study.
- Company's explanation for the G&A increase: primarily due to increases in non-cash stock-based compensation and professional fees.
- Interest income rose from $292 thousand to $1,218 thousand for the quarter, as printed in the statement of operations; the filing does not state a cause for this change.
- Clinical programs: REGAL topline primary endpoint results are expected in November 2026 following the 80th event; SLS009 Phase 2 r/r AML data is slated for the ASH Annual Meeting on December 12 to 15, 2026; preliminary topline data from the newly diagnosed AML Phase 2 trial is expected in Q4 2026.
Concerns
- No revenue is reported in either period; the company reports only operating expenses and interest income.
- Net loss for the quarter was $(10,091) thousand versus $(6,791) thousand a year earlier, and for the nine months $(28,103) thousand versus $(19,205) thousand.
- Operating expenses grew in both periods, with R&D up from $4,216 thousand to $7,029 thousand for the quarter and G&A up from $2,867 thousand to $4,280 thousand.
- Weighted-average common shares outstanding were 202,437,078 for the quarter versus 108,396,260 a year earlier, as printed, so the per-share loss is reported on a substantially larger share base.
- Accumulated deficit increased from $(274,988) thousand to $(303,091) thousand since December 31, 2025, as printed.
- The outcome of the Phase 3 REGAL primary endpoint analysis is not yet disclosed; the filing states results are expected this month.
What to watch
- Topline primary endpoint results of the Phase 3 REGAL trial of GPS in AML, expected in November 2026, and the company's subsequent regulatory plans, including the potential BLA referenced in the filing.
- Presentation of Phase 2 r/r AML data for SLS009 at the ASH Annual Meeting, December 12 to 15, 2026.
- Preliminary topline data from the 80-patient Phase 2 trial of SLS009 in newly diagnosed AML, expected in Q4 2026; 40 patients enrolled as of the filing.
- Trajectory of R&D and G&A expense, given the company's stated preparations for a potential BLA and the non-cash stock-based compensation increase.
- Cash burn against the $134,711 thousand cash balance; the filing does not print operating or free cash flow.
Balance sheet and cash flow
- Cash and cash equivalents: $134,711 thousand at September 30, 2026 (release text: approximately $134.7 million) versus $71,793 thousand at December 31, 2025.
- Total assets: $141,091 thousand at September 30, 2026 versus $78,345 thousand at December 31, 2025.
- Total liabilities: $9,286 thousand at September 30, 2026 versus $7,474 thousand at December 31, 2025.
- Total stockholders' equity: $131,805 thousand at September 30, 2026 versus $70,871 thousand at December 31, 2025.
- Additional paid-in capital: $434,876 thousand at September 30, 2026 versus $345,844 thousand at December 31, 2025.
- Accumulated deficit: $(303,091) thousand at September 30, 2026 versus $(274,988) thousand at December 31, 2025.
- Shares issued and outstanding: 203,527,833 at September 30, 2026 versus 153,103,459 at December 31, 2025, as printed in the balance sheet caption.
- Restricted cash and cash equivalents: $100 thousand at both dates as printed.
Analysis
SELLAS reported no revenue for the quarter or the nine months ended September 30, 2026. The results consist of operating expenses and interest income, which together produced a net loss of $(10,091) thousand for the quarter, compared with $(6,791) thousand in the third quarter of 2025, and $(28,103) thousand for the nine months, compared with $(19,205) thousand a year earlier. Research and development expense was $7,029 thousand for the quarter versus $4,216 thousand, and $18,430 thousand for the nine months versus $11,292 thousand. The company attributes the R&D increase to higher manufacturing costs, clinical and regulatory consulting, and clinical trial expenses in preparation for a potential BLA for GPS after the REGAL final analysis.
General and administrative expense rose to $4,280 thousand for the quarter from $2,867 thousand, and to $12,760 thousand for the nine months from $8,727 thousand. The company says this increase was primarily due to non-cash stock-based compensation and professional fees. Interest income increased to $1,218 thousand for the quarter from $292 thousand and to $3,087 thousand for the nine months from $814 thousand; the filing does not give a cause for this change.
The balance sheet shows total assets of $141,091 thousand and cash and cash equivalents of $134,711 thousand at September 30, 2026, against $78,345 thousand and $71,793 thousand at December 31, 2025. Total stockholders' equity rose to $131,805 thousand from $70,871 thousand. Additional paid-in capital rose to $434,876 thousand from $345,844 thousand, and shares outstanding rose to 203,527,833 from 153,103,459, as printed. The filing does not include a cash flow statement, so operating cash use is not reported here.
The filing provides no financial guidance, so there is no prior outlook to compare against. The primary items for the reader are the clinical milestones: topline primary endpoint results from the Phase 3 REGAL trial of GPS, which the company expects to announce in November 2026; Phase 2 relapsed/refractory AML data for SLS009 at ASH in December 2026; and preliminary topline data from the newly diagnosed AML Phase 2 trial in Q4 2026. The REGAL result is not yet in the document and is the event that will most affect how the cash position and expense trajectory are read.
Management, verbatim
We continue to execute across both of our clinical programs as we approach several important milestones.
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month.
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs.
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
Not in the filing
stated, not guessed- Percentage year-over-year changes for any line item are not printed; yoy_change fields are null.
- Prior-quarter (Q2 2026) figures are not printed in this release; qoq_change and prior_quarter fields are null.
- Company-level revenue is not reported; the filing shows no revenue line.
- No segment or product-level breakdown is provided.
- No financial guidance or outlook is provided, and no prior-period outlook was supplied for comparison.
- No cash flow statement, operating cash flow, free cash flow or capital expenditure figures are printed.
- No debt, borrowings or credit facility figures are printed.
- Balance sheet comparison is to December 31, 2025, not to September 30, 2025.
- No share repurchases, dividends or other capital return activity is printed.
- The release does not state a cause for the increase in interest income or for the increase in shares outstanding.
- No analyst consensus, price target or share price reaction is included in the document.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a late‑stage oncology biotech reporting its Q3 2026 financials and clinical updates via an SEC 8‑K.
Ticker impact
SEC 8‑K filing reports Q3 2026 results, cash balance of $134.7 M and upcoming Phase 3 and Phase 2 trial data.
likely pressure as investors digest the widened loss and higher expenses, with upside only if Phase 3/2 data exceed expectations
The filing provides fresh financial numbers and a timeline for pivotal clinical data, both of which are primary drivers of biotech stock moves.
Market effects
Adds to the pipeline‑risk narrative for late‑stage oncology biotechs, may influence sector sentiment ahead of upcoming AML trial readouts.
Limited to U.S. biotech investors; no broader regional effect.
Modest, confined to specialty pharma/biotech niche.
Counterpoint
If the Phase 3 REGAL trial delivers strong efficacy, the stock could rally sharply despite the quarterly loss.
Key entities
- companySELLAS Life Sciences Group, Inc.
NASDAQ‑listed biotech focused on AML and CDK9 inhibitor programs.
- executiveAngelos Stergiou
President and CEO of SELLAS, quoted in the filing.
